Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Inclusion Criteria: 1. Newly diagnosed, treatment naïve ITP patients 2. Patients with a platelet count \<30,000/μL or a platelet count \<50,000/μL with bleeding manifestations at the enrollment; 3. Willing and able to sign written informed consent. Exclusion Criteria: 1. Received first-line and second-line ITP-modifying therapy (any previous dose of corticosteroids or other immune-suppressive agents); 2. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit; 3. Active or a history of malignancy; 4. Positive test result for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV); 5. Pregnancy or lactation; 6. Pre-existing acute or chronic liver disease, or serum alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (ULN); 7. Current or recent (\<4 weeks before screening) clinically serious viral, bacterial, fungal, or parasitic infection; 8. A known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test; 9. Patients who are deemed unsuitable for the study by the investigator.